Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEGARELIX ACETATE vs ACULAR LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Treatment of advanced prostate cancer
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.
1 drop in the affected eye(s) four times daily
Terminal elimination half-life is approximately 43-73 days after subcutaneous administration, reflecting slow release from the depot formulation.
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Hepatic via hydrolysis of the acetate ester; no significant CYP450 involvement.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Renal elimination accounts for approximately 20-30% of the dose as unchanged drug; fecal elimination accounts for 70-80% primarily as metabolites.
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
Approximately 1 L/kg, indicating extensive distribution into tissues.
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Subcutaneous: approximately 100% for the depot formulation; not available orally due to peptide degradation.
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
No dose adjustment required for GFR ≥15 m L/min. Insufficient data for GFR <15 m L/min or dialysis; use caution.
No dosage adjustment required for renal impairment
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
Safety and efficacy not established in pediatric patients; no recommended dosing.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
No specific dose adjustment required; similar efficacy and safety observed in elderly patients (≥65 years) compared to younger adults.
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
None
None
Hypersensitivity reactions including anaphylaxis and angioedema,QT interval prolongation,Laboratory test interference with gonadotropin and gonadal steroid assays,Injection site reactions including pain and erythema,Bone density loss,Hyperglycemia and increased risk of diabetes
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
Hypersensitivity to degarelix or any component of the formulation,Pregnancy (potential fetal harm)
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
No specific food interactions have been identified. Degarelix is administered parenterally and does not interact with dietary components. Avoid grapefruit juice if concurrent QT-prolonging drugs are used, but not a direct interaction with degarelix.
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential for fetal androgen deprivation leading to ambiguous genitalia in male fetuses.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
No data available on excretion in human milk; potential for serious adverse effects in nursing infants; discontinue breastfeeding or discontinue drug.
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
No dose adjustments are applicable as degarelix is contraindicated in pregnancy; therapy must be discontinued if pregnancy occurs.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
Degarelix acetate is a Gn RH antagonist used for advanced prostate cancer. It provides rapid testosterone suppression without the initial testosterone surge seen with Gn RH agonists. Monitor serum testosterone and PSA levels; castrate levels (<50 ng/d L) typically achieved within 3 days. Injection site reactions are common; rotate injection sites (abdomen, thigh, buttock). Avoid in patients with known QT prolongation or concurrent QT-prolonging drugs. Contraindicated in women and children.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
Degarelix is given as a subcutaneous injection by a healthcare provider every month (or every 2 months for maintenance dose) to treat advanced prostate cancer.,Do not miss scheduled injections because consistent dosing is needed to keep testosterone levels low.,Common side effects include injection site pain, redness, or swelling; hot flashes; increased liver enzymes; and weight gain.,Report signs of allergic reaction (rash, itching, difficulty breathing) or prolonged QT interval (fainting, palpitations) to your doctor immediately.,Degarelix may cause bone thinning; discuss calcium and vitamin D supplementation with your doctor.,This drug can cause harm to a fetus; not for use in women or children.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
"Asenapine, a second-generation antipsychotic, is associated with dose-dependent QTc interval prolongation due to its inhibitory effects on cardiac potassium channels (specifically IKr). Degarelix, a GnRH antagonist used in prostate cancer, may also cause QTc prolongation, likely through hormonal suppression mechanisms. Coadministration can result in additive QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with pre-existing risk factors."
"Dolasetron, a 5-HT3 receptor antagonist, is known to cause dose-dependent prolongation of the QT interval by blocking cardiac potassium channels. When coadministered with Degarelix, a GnRH receptor antagonist that also reduces testosterone levels and can induce QT prolongation via electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) or direct cardiac effects, the risk of additive QT prolongation is increased. This may lead to a higher propensity for torsade de pointes and other ventricular arrhythmias, particularly in patients with pre-existing risk factors."
"Cabazitaxel is a taxane antineoplastic agent that undergoes extensive hepatic metabolism via CYP3A4/5 and is a substrate of P-glycoprotein. Degarelix, a GnRH antagonist, has no known direct metabolic interaction with Cabazitaxel but may theoretically increase the risk of QT prolongation when combined with other drugs. However, the baseline description is vague; the interaction is not well-established and possibly refers to additive myelosuppression or cardiovascular effects from overlapping toxicities."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEGARELIX ACETATE vs ACULAR LS, answered by our medical review team.
DEGARELIX ACETATE is a GnRH antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.. ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEGARELIX ACETATE and ACULAR LS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEGARELIX ACETATE is: Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.. The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEGARELIX ACETATE and ACULAR LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEGARELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential . ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.